thalidomide has been researched along with Diathesis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma." | 2.61 | IMiDs New and Old. ( Ruan, J; Yamshon, S, 2019) |
| "Autoimmune diseases are prevalent among MDS patients." | 1.43 | Autoimmune diseases and myelodysplastic syndromes. ( Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chowdhury, O | 1 |
| O'Sullivan, J | 1 |
| Barkas, N | 1 |
| Wang, G | 1 |
| Buck, G | 1 |
| Hamblin, A | 1 |
| Tefferi, A | 1 |
| Al-Ali, HK | 1 |
| Barosi, G | 1 |
| Devos, T | 1 |
| Gisslinger, H | 1 |
| Jiang, Q | 1 |
| Kiladjian, JJ | 1 |
| Mesa, R | 1 |
| Passamonti, F | 1 |
| Ribrag, V | 1 |
| Schiller, G | 1 |
| Vannucchi, AM | 1 |
| Zhou, D | 1 |
| McMullin, MF | 1 |
| Zhong, J | 1 |
| Gale, RP | 2 |
| Mead, AJ | 1 |
| Curtis, LM | 1 |
| Ostojic, A | 1 |
| Venzon, DJ | 1 |
| Holtzman, NG | 1 |
| Pirsl, F | 1 |
| Kuzmina, ZJ | 1 |
| Baird, K | 1 |
| Rose, JJ | 1 |
| Cowen, EW | 1 |
| Mays, JW | 1 |
| Mitchell, SA | 1 |
| Parsons-Wandell, L | 1 |
| Joe, GO | 1 |
| Comis, LE | 1 |
| Berger, A | 1 |
| Pusic, I | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Cao, L | 1 |
| Hakim, FT | 1 |
| Pavletic, SZ | 1 |
| Yamshon, S | 1 |
| Ruan, J | 1 |
| Cozzani, E | 1 |
| Gasparini, G | 1 |
| Parodi, A | 1 |
| Komrokji, RS | 1 |
| Kulasekararaj, A | 1 |
| Al Ali, NH | 1 |
| Kordasti, S | 1 |
| Bart-Smith, E | 1 |
| Craig, BM | 1 |
| Padron, E | 1 |
| Zhang, L | 1 |
| Lancet, JE | 1 |
| Pinilla-Ibarz, J | 1 |
| List, AF | 1 |
| Mufti, GJ | 1 |
| Epling-Burnette, PK | 1 |
2 reviews available for thalidomide and Diathesis
| Article | Year |
|---|---|
IMiDs New and Old.
Topics: Animals; Antineoplastic Agents; Biomarkers; Disease Susceptibility; Drug Resistance, Neoplasm; Hemat | 2019 |
Pyoderma gangrenosum: a systematic review.
Topics: Anti-Inflammatory Agents; Arthritis; Dermatologic Agents; Diagnosis, Differential; Disease Progressi | 2014 |
1 trial available for thalidomide and Diathesis
| Article | Year |
|---|---|
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Allografts; Disease Susceptibility; Dose-Response Relationship, Drug; Drug | 2021 |
2 other studies available for thalidomide and Diathesis
| Article | Year |
|---|---|
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Topics: Disease Management; Disease Susceptibility; Erythrocyte Transfusion; Humans; Mutation; Myeloprolifer | 2021 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; | 2016 |